September 18, 2013
The European Commission's Seventh Framework Program will award $801,360 throughout three years to scientific software company Qlucore to develop algorithms for use in personalizing hepatitis C treatment. The company will work on mathematical and statistical algorithms for integrating information from genetic, proteomic, and clinical research data to provide clinicians with a mobile application that could be used at the point of care. Pharmaceutical companies currently are developing new hepatitis C drugs that would lead to more genetic and clinical variables to evaluate for patients and create a need for tools that could assist clinicians in prescribing custom treatments for each patient.
09.16.2013; Ryan McBride
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|CROI 2017 Preview: New Research on HIV Cure and Treatment|
|No Evidence of Accelerated Brain Aging in HIV-Positive People on Effective ART|
|Final HIV Research Highlights From CROI 2017|
|Research Shows 47% Reduction in STIs Among Gay Men Who Took Doxycycline After Sex|
|What to Expect for CROI 2017|
|Don't Get Left Behind: New Scientific Findings to Be Presented at CROI 2017|